B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
B7-H3 and B7x are recently discovered members of the B7-CD28 family thought to dampen peripheral immune responses via negative costimulation. We evaluated their potential expression in human prostate cancer using a large cohort of patients with 7 years of follow-up. We identified 823 patients with tissue available treated with radical prostatectomy between 1985 and 2003. Immunohistochemistry was performed on tissue microarray sections using anti-B7-H3 and -B7x. The percentage and intensity of immunoreactivity by tumor cells were blindly evaluated by two urological pathologists, and outcome analyses were conducted. Both B7-H3 and B7x were highly expressed; 93% and 99% of tumors had aberrant expression, respectively. The median percentage of tumor cells staining positive was 80% for each molecule. Strong intensity for B7-H3 and B7x was noted in 212 (26%) and 120 (15%) patients, respectively. Patients with strong intensity for B7-H3 and B7x were significantly more likely to have disease spread at time of surgery ( P < 0.001 and P = 0.005, respectively). Additionally, patients with strong intensity for B7-H3 and B7x were at significantly increased risk of clinical cancer recurrence ( P < 0.001 and P = 0.005) and cancer-specific death ( P = 0.004 and P = 0.04, respectively). To our knowledge, we present the largest investigation of B7 family molecules in a human malignancy and a previously undescribed evaluation of B7x in prostate cancer. B7-H3 and B7x are abundantly expressed in prostate cancer and associated with disease spread and poor outcome. Given the proposed immune-inhibitory mechanisms of B7-H3 and B7x, these molecules represent attractive targets for therapeutic manipulation in prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As a result, overexpression of B7H3 is associated with disease spread, including increased extracapsular extension and seminal vesicle invasion, as well as worse outcomes, including higher risk of metastatic recurrence or subsequent development of CRPC88.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citationDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Self-citationHamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
Townsend, S. E., & Allison, J. P. (1993) · Science · doi:10.1126/science.7678351 · Cited by 1,136
Self-citationB7-H3: A costimulatory molecule for T cell activation and IFN-γ production
Chapoval, A. I., Ni, J., Lau, J. S., Wilcox, R. A., Flies, D. B., Liu, D., Dong, H., Sica, G. L., Zhu, G., Tamada, K., et al. (2001) · Nature Immunology · doi:10.1038/85339 · Cited by 1,015
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Self-citation
Cited by
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
Poggio, M., Hu, T., Pai, C.-C., Chu, B., Belair, C. D., Chang, A., Montabana, E., Lang, U. E., Fu, Q., Fong, L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.016 · Cited by 1,376
“…Secretion of PD-L1 between CancerCell Lines It has been reported that surface PD-L1 levels are low in prostate cancer cell lines and primary prostate tumor tissue, potentially explaining the general lack of therapeutic response to anti-PDL1 blockade (Martin et al., 2015; Zang et al., 2007).”
BackgroundMolecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
Picarda, E., Ohaegbulam, K. C., & Zang, X. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2428 · Cited by 582
Self-citationDu, H., Hirabayashi, K., Ahn, S., Kren, N. P., Montgomery, S. A., Wang, X., Tiruthani, K., Mirlekar, B., Michaud, D., Greene, K., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.002 · Cited by 479
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin, D. S., & Ribas, A. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.006 · Cited by 346
Lee, Y.-H., Martin-Orozco, N., Zheng, P., Li, J., Zhang, P., Tan, H., Park, H. J., Jeong, M., Chang, S. H., Kim, B.-S., et al. (2017) · Cell Research · doi:10.1038/cr.2017.90 · Cited by 328
Emerging targets in cancer immunotherapy
Burugu, S., Dancsok, A. R., & Nielsen, T. O. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.001 · Cited by 314
Brady, L., Kriner, M., Coleman, I., Morrissey, C., Roudier, M., True, L. D., Gulati, R., Plymate, S. R., Zhou, Z., Birditt, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21615-4 · Cited by 297
B7‐H3 is a potent inhibitor of human T‐cell activation: No evidence for B7‐H3 and TREML2 interaction
Leitner, J., Klauser, C., Pickl, W. F., Stöckl, J., Majdic, O., Bardet, A. F., Kreil, D. P., Dong, C., Yamazaki, T., Zlabinger, G., et al. (2009) · European Journal of Immunology · doi:10.1002/eji.200839028 · Cited by 290
Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity
Loo, D., Alderson, R. F., Chen, F. Z., Huang, L., Zhang, W., Gorlatov, S., Burke, S., Ciccarone, V., Li, H., Yang, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0715 · Cited by 284
“In this report we have described identification and characterization of a panel of mAbs with specificity for B7-H3, a protein over-expressed on many cancers, including prostate (15, 16, 17), renal (18), pancreatic (19, 20), colorectal (21), non-small cell lung (22), ovarian (23), bladder (24), melanoma (25), and neuro…”
BackgroundShifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Quezada, S. A., Peggs, K. S., Simpson, T. R., & Allison, J. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01007.x · Cited by 276
Self-citationSouweidane, M. M., Kramer, K., Pandit-Taskar, N., Zhou, Z., Haque, S., Zanzonico, P., Carrasquillo, J. A., Lyashchenko, S. K., Thakur, S. B., Donzelli, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30322-x · Cited by 267
Xu, H., Cheung, I. Y., Guo, H.-F., & Cheung, N.-K. V. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4517 · Cited by 264
Novel diagnostic biomarkers for prostate cancer
Madu, C. O., & Lu, Y. (2010) · Journal of Cancer · doi:10.7150/jca.1.150 · Cited by 261
Kim, J. W., Nam, K. H., Ahn, S.-H., Park, D. J., Kim, H.-H., Kim, S. H., Chang, H., Lee, J.-O., Kim, Y. J., Lee, H. S., et al. (2016) · Gastric Cancer · doi:10.1007/s10120-014-0440-5 · Cited by 250
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas
Zang, X., Sullivan, P. S., Soslow, R. A., Waitz, R., Reuter, V. E., Wilton, A., Thaler, H. T., Arul, M., Slovin, S. F., Wei, J., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.95 · Cited by 249
Self-citationNew B7 Family Checkpoints in Human Cancers
Ni, L., & Dong, C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0761 · Cited by 244
“Recent studies found that aberrant B7-H3 was expressed on awide variety of cancers, including lung (5), prostate (6), kidney (7), ovary (8), endometrium (9), colorectum (10), liver (11), and breast (12).”
BackgroundCell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00649.x · Cited by 229
Self-citationHashiguchi, M., Kobori, H., Ritprajak, P., Kamimura, Y., Kozono, H., & Azuma, M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802423105 · Cited by 227
The third group of the B7‐CD 28 immune checkpoint family: HHLA 2, TMIGD 2, B7x, and B7‐H3
Janakiram, M., Shah, U. A., Liu, W., Zhao, A., Schoenberg, M. P., & Zang, X. (2017) · Immunological Reviews · doi:10.1111/imr.12521 · Cited by 225
Self-citationCurrent Status of Biomarkers for Prostate Cancer
Velonas, V., Woo, H., Remedios, C., & Assinder, S. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140611034 · Cited by 216
Li, J., Lee, Y., Li, Y., Jiang, Y., Lu, H., Zang, W., Zhao, X., Liu, L., Chen, Y., Tan, H., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.018 · Cited by 209
A gene expression signature of TREM2hi macrophages and γδ T cells predicts immunotherapy response
Xiong, D., Wang, Y., & You, M. (2020) · Nature Communications · doi:10.1038/s41467-020-18546-x · Cited by 208
Pentcheva‐Hoang, T., Corse, E., & Allison, J. P. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00763.x · Cited by 203
Self-citationHofmeyer, K. A., Ray, A., & Zang, X. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805458105 · Cited by 201
Self-citationYao, Y., Ye, H., Qi, Z., Mo, L., Yue, Q., Baral, A., Hoon, D. S. B., Vera, J. C., Heiss, J. D., Chen, C. C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0858 · Cited by 188
Self-citationThe role of B7 family molecules in hematologic malignancy
Greaves, P., & Gribben, J. G. (2013) · Blood · doi:10.1182/blood-2012-10-385591 · Cited by 187
PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
Crane, C. A., Panner, A., Murray, J. C., Wilson, S. P., Xu, H., Chen, L., Simko, J. P., Waldman, F. M., Pieper, R. O., & Parsa, A. T. (2009) · Oncogene · doi:10.1038/onc.2008.384 · Cited by 181
Wang, L., Zhang, Q., Chen, W., Shan, B., Ding, Y., Zhang, G., Cao, N., Liu, L., & Zhang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070689 · Cited by 177
Fine tuning the immune response through B7‐H3 and B7‐H4
Yi, K. H., & Chen, L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00768.x · Cited by 175
Chen, X., Song, X., Li, K., & Zhang, T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00292 · Cited by 174
Shimizu, T., Ishikawa, T., Sugihara, E., Kuninaka, S., Miyamoto, T. K., Mabuchi, Y., Matsuzaki, Y., Tsunoda, T., Miya, F., Morioka, H., et al. (2010) · Oncogene · doi:10.1038/onc.2010.312 · Cited by 172
Benzon, B., Zhao, S. G., Haffner, M. C., Takhar, M., Erho, N., Yousefi, K., Hurley, P., Bishop, J. L., Tosoian, J., Ghabili, K., et al. (2017) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.49 · Cited by 170
Clinical importance of B7-H3 expression in human pancreatic cancer
Yamato, I., Sho, M., Nomi, T., Akahori, T., Shimada, K., Hotta, K., Kanehiro, H., Konishi, N., Yagita, H., & Nakajima, Y. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605375 · Cited by 169
B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma
Zhou, Z., Luther, N., Ibrahim, G. M., Hawkins, C. E., Vibhakar, R., Handler, M. H., & Souweidane, M. M. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1021-2 · Cited by 160
Tekle, C., Nygren, M. K., Chen, Y., Dybsjord, I., Nesland, J. M., Mælandsmo, G. M., & Fodstad, Ø. (2012) · International Journal of Cancer · doi:10.1002/ijc.26238 · Cited by 159
Potential targeting of B7‐H4 for the treatment of cancer
Podojil, J. R., & Miller, S. D. (2017) · Immunological Reviews · doi:10.1111/imr.12530 · Cited by 159
Sun, J., Chen, L.-J., Zhang, G.-B., Jiang, J.-T., Zhu, M., Tan, Y., Wang, H.-T., Lu, B.-F., & Zhang, X.-G. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0841-1 · Cited by 159
“This result was further confirmed by an expanded sample in tissue microarray [ 33 ].”
ResultScribner, J. A., Brown, J. G., Son, T., Chiechi, M., Li, P., Sharma, S., Li, H., De Costa, A., Li, Y., Chen, Y., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0116 · Cited by 158
B7-H3 Silencing Increases Paclitaxel Sensitivity by Abrogating Jak2/Stat3 Phosphorylation
Liu, H., Tekle, C., Chen, Y.-W., Kristian, A., Zhao, Y., Zhou, M., Liu, Z., Ding, Y., Wang, B., Mælandsmo, G. M., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0072 · Cited by 159
“Notably, immunohistochemical reports have shown a correlation between high expression of B7-H3 and poor outcome in patients with breast cancer (6), clear cell renal cell carcinoma (7), urothelial cell carcinoma (8), prostate cancer (9), non– small cell lung cancer (10), and pancreatic cancer (11).”
BackgroundYin–Yang of costimulation: crucial controls of immune tolerance and function
Nurieva, R. I., Liu, X., & Dong, C. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00769.x · Cited by 157
Loos, M., Hedderich, D. M., Ottenhausen, M., Giese, N. A., Laschinger, M., Esposito, I., Kleeff, J., & Friess, H. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-463 · Cited by 151
New checkpoints in cancer immunotherapy
Ni, L., & Dong, C. (2017) · Immunological Reviews · doi:10.1111/imr.12524 · Cited by 142
Lemke, D., Pfenning, P., Sahm, F., Klein, A.-C., Kempf, T., Warnken, U. H., Schnölzer, M., Tudoran, R., Weller, M., Platten, M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0880 · Cited by 144
“Experimental Design: To characterize B7H3 in glioblastoma, we conduct analyses not only in glioma cell lines and glioma-initiating cells but also in human glioma tissue specimens.”
BackgroundXu, W., Hiếu, T., Malarkannan, S., & Wang, L. L. (2018) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.148 · Cited by 145
Liu, S., Liang, J., Liu, Z., Zhang, C., Wang, Y., Watson, A. H., Zhou, C., Zhang, F., Wu, K., Zhang, F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.654684 · Cited by 144
B7‐H3‐mediated tumor immunology: Friend or foe?
Wang, L., Kang, F., & Shan, B. (2013) · International Journal of Cancer · doi:10.1002/ijc.28474 · Cited by 140
Structure and T Cell Inhibition Properties of B7 Family Member, B7-H3
Vigdorovich, V. I., Ramagopal, U. A., Lázár‐Molnár, E., Sylvestre, E., Lee, J. S., Hofmeyer, K. A., Zang, X., Nathenson, S. G., & Almo, S. C. (2013) · Structure · doi:10.1016/j.str.2013.03.003 · Cited by 140
Self-citationGlycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response
Chen, J., Chen, C., Ku, K.-L., Hsiao, M., Chiang, C., Hsu, T.-L., Chen, M., & Wong, C. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1516991112 · Cited by 140
B7H3 As a Promoter of Metastasis and Promising Therapeutic Target
Dong, P., Xiong, Y., Yue, J., Hanley, S. J. B., & Watari, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00264 · Cited by 139
“Prostate cancer 823 IHC Upregulation NA NA + + Poor (37)”
BackgroundExtracellular Vesicles in Prostate Cancer Carcinogenesis, Diagnosis, and Management
Vlaeminck‐Guillem, V. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00222 · Cited by 137
Geng, Y., Wang, H., Chang-qing, L., Li, Q., Xu, B., Jiang, J., & Wu, C. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-014-0701-7 · Cited by 128
“RCC and prostate carcinoma patients with B7-H4-positive tumors usually have a high risk of recurrence and death [30].”
BackgroundChen, L., Sun, J., Wu, H., Zhou, S.-M., Tan, Y. Q., Tan, M., Shan, B.-E., Lu, B., & Zhang, X. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1017-3 · Cited by 127
“Aberrant B7-H4 expression was also found in prostate cancer, and strong expression of B7-H4 is positively correlated with extra capsular extension, seminal vesicle invasion, and distant metastasis [25].”
BackgroundLaniti, D. D., Lanitis, E., Zhao, A., Joshi, S., Cheng, Y., Sandaltzopoulos, R., Ra, H.-J., Danet-Desnoyers, G. A., Powell, D. J., & Scholler, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3457 · Cited by 126
The Future of Immune Checkpoint Cancer Therapy After PD-1 and CTLA-4
Hahn, A. W., Gill, D. M., Pal, S. K., & Agarwal, N. (2017) · Immunotherapy · doi:10.2217/imt-2017-0024 · Cited by 117
Zhao, J., Lei, T., Xu, C., Li, H., Ma, W., Yang, Y., Fan, S., & Liu, Y. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.07.095 · Cited by 123
Ingebrigtsen, V. A., Boye, K., Tekle, C., Nesland, J. M., Flatmark, K., & Fodstad, Ø. (2012) · International Journal of Cancer · doi:10.1002/ijc.27566 · Cited by 123
B7‐H3 and Its Role in Antitumor Immunity
Loos, M., Hedderich, D. M., Friess, H., & Kleeff, J. H. (2010) · Journal of Immunology Research · doi:10.1155/2010/683875 · Cited by 123
Ahmed, M., Cheng, M., Zhao, Q., Goldgur, Y., Cheal, S. M., Guo, H.-F., Larson, S. M., & Cheung, N.-K. V. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679852 · Cited by 117
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
Guo, C. W., Figueiredo, I., Gürel, B., Neeb, A., Seed, G., Crespo, M., Carreira, S., Rekowski, J., Buroni, L., Welti, J. C., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.09.004 · Cited by 120
Dondero, A., Pastorino, F., Chiesa, M. D., Corrias, M. V., Morandi, F., Pistoia, V., Olive, D., Bellora, F., Locatelli, F., Castellano, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1064578 · Cited by 120
Gaudreau, P.-O., Stagg, J., Soulières, D., & Saad, F. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s31802 · Cited by 115
Sun, T., Gao, Q., Qiu, S., Zhou, J., Wang, X., Yi, Y., Shi, J.-Y., Xu, Y., Shi, Y., Song, K., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1278-5 · Cited by 114
B7-H4, a promising target for immunotherapy
Wang, J., & Wang, W. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.104008 · Cited by 112
Bottino, C., Dondero, A., Bellora, F., Moretta, L., Locatelli, F., Pistoia, V., Moretta, A., & Castriconi, R. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00056 · Cited by 108
Chen, C., Shen, Y., Qu, Q., Chen, X., Zhang, X., & Huang, J. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.09.006 · Cited by 108
The complex role of B7 molecules in tumor immunology
Seliger, B., Marincola, F. M., Ferrone, S., & Abken, H. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.09.010 · Cited by 91
Liu, Z., Zhang, W., Phillips, J. B., Arora, R., McClellan, S. B., Li, J., Kim, J. H., Sobol, R. W., & Tan, M. (2018) · Oncogene · doi:10.1038/s41388-018-0407-9 · Cited by 106
The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview
Schaft, N. (2020) · Cancers · doi:10.3390/cancers12092567 · Cited by 99
Cheng, H., Janakiram, M., Borczuk, A., Lin, J., Qiu, W., Liu, H., Chinai, J. M., Halmos, B., Perez-Soler, R., & Zang, X. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3071 · Cited by 104
Self-citationLarge-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma
Zhang, C., Zhang, Z., Li, F., Shen, Z., Qiao, Y., Li, L., Liu, S., Song, M., Zhao, X., Ren, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1461304 · Cited by 104
“In addition, studies have found that increased B7-H3 expression shows a direct correlation with shortened overall survival (OS).(11,12) With a preferen-”
BackgroundThe CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy
Leung, J., & Suh, W. (2014) · Immune Network · doi:10.4110/in.2014.14.6.265 · Cited by 103
Yamato, M., Hasegawa, J., Maejima, T., Hattori, C., Kumagai, K., Watanabe, A., Nishiya, Y., Shibutani, T., Aida, T., Hayakawa, I., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0554 · Cited by 102
Immunoexpression of B7-H3 in endometrial cancer: Relation to tumor T-cell infiltration and prognosis
Brunner, A. H., Hinterholzer, S., RISS, P. A., Heinze, G., & Brustmann, H. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.012 · Cited by 101
Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer
Jiang, J., Zhu, Y., Wu, C., Shen, Y., Wei, W., Chen, L., Zheng, X. W., Sun, J., Lu, B., & Zhang, X. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0900-7 · Cited by 97
“Patients with a strong intensity of B7-H4 were signiWcantly more likely to have disease spread at the time of surgery and at signiWcantly higher risk of cancer recurrence and cancer-related death [34].”
BackgroundB7-H3 Over Expression in Prostate Cancer Promotes Tumor Cell Progression
Yuan, H., Wei, X., Zhang, G., Li, C., Zhang, X., & Hou, J. (2011) · The Journal of Urology · doi:10.1016/j.juro.2011.04.103 · Cited by 96
Shi, W. M., Wang, Y., Zhao, Y., Kim, J. J., Li, H., Meng, C., Chen, F., Zhang, J., Mak, D. H. F., Van, V., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf6724 · Cited by 94
Ingebrigtsen, V. A., Boye, K., Nesland, J. M., Nesbakken, A., Flatmark, K., & Fodstad, Ø. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-602 · Cited by 92
The Immune Microenvironment in Prostate Cancer: A Comprehensive Review
Novysedlák, R., Guney, M., Khouri, M. A., Bartolini, R., Foley, L. K., Benešová, I., Ozaniak, A., Novák, V., Veselý, Š., Pacas, P., et al. (2024) · Oncology · doi:10.1159/000541881 · Cited by 91
Diagnosis value of serum B7-H3 expression in non-small cell lung cancer
Zhang, G., Xu, Y., Lü, X., Huang, H., Zhou, Y., Lu, B., & Zhang, X. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.01.017 · Cited by 91
Cheng, H., Borczuk, A., Janakiram, M., Ren, X., Lin, J., Assal, A., Halmos, B., Perez-Soler, R., & Zang, X. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2924 · Cited by 90
Self-citationB7-H3 promotes gastric cancer cell migration and invasion
Li, Y., Yang, X., Wu, Y., Zhao, K., Ye, Z., Zhu, J., Xu, X., Zhao, X., & Xing, C. (2017) · Oncotarget · doi:10.18632/oncotarget.17847 · Cited by 88
Serum-Soluble B7x Is Elevated in Renal Cell Carcinoma Patients and Is Associated with Advanced Stage
Thompson, R. H., Zang, X., Lohse, C. M., Leibovich, B. C., Slovin, S. F., Reuter, V. E., Cheville, J. C., Blute, M. L., Russo, P., Kwon, E. D., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0869 · Cited by 89
Self-citationThe expression, function, and clinical relevance of B7 family members in cancer
Seliger, B., & Quandt, D. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1293-6 · Cited by 85
Nunes‐Xavier, C. E., Karlsen, K. F., Tekle, C., Pedersen, C., Øyjord, T., Hongisto, V., Nesland, J. M., Tan, M., Sahlberg, K. K., & Fodstad, Ø. (2016) · Oncotarget · doi:10.18632/oncotarget.6902 · Cited by 85
Expression of Immunosuppresive B7-H3 Ligand by Hormone-Treated Prostate Cancer Tumors and Metastases
Chavin, G., Sheinin, Y. M., Crispen, P. L., Boorjian, S. A., Roth, T. J., Rangel, L. J., Blute, M. L., Sebo, T. J., Tindall, D., Kwon, E. D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2262 · Cited by 84
B7-H3 Immune Checkpoint Protein in Human Cancer
Karlsen, K. F., Fodstad, Ø., & Nunes‐Xavier, C. E. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190517115515 · Cited by 87
A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer
Fauci, J. M., Straughn, J. M., Ferrone, S., & Buchsbaum, D. J. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.08.017 · Cited by 83
Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target
MacGregor, H. L., & Ohashi, P. S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2440 · Cited by 81
Zhao, L.-W., Li, C., Zhang, R.-L., Xue, H., Fu-xi, Z., Zhang, F., & Gai, X. (2014) · Acta Histochemica · doi:10.1016/j.acthis.2014.06.003 · Cited by 80
Rational combinations of immunotherapeutics that target discrete pathways
Spranger, S., & Gajewski, T. F. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-16 · Cited by 82
Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 80
Structure and Cancer Immunotherapy of the B7 Family Member B7x
Jeon, H., Vigdorovich, V., Garrett-Thomson, S. C., Janakiram, M., Ramagopal, U. A., Abadi, Y. M., Lee, J. S., Scandiuzzi, L., Ohaegbulam, K. C., Chinai, J. M., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.09.053 · Cited by 76
Self-citationNews on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
Melaiu, O., Lucarini, V., Giovannoni, R., Fruci, D., & Gemignani, F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.001 · Cited by 79
Zhan, S., Liu, Z., Zhang, M., Guo, T., Quan, Q., Huang, L., Guo, L., Cao, L., & Zhang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01466 · Cited by 78
The Inhibitory Role of B7-H4 in Antitumor Immunity: Association with Cancer Progression and Survival
He, C., Qiao, H., Jiang, H., & Sun, X. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/695834 · Cited by 76
Immune checkpoint inhibitors and prostate cancer: a new frontier?
Modena, A., Ciccarese, C., Iacovelli, R., Brunelli, M., Montironi, R., Fiorentino, M., Tortora, G., & Massari, F. (2016) · Oncology Reviews · doi:10.4081/oncol.2016.293 · Cited by 75
The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial
John, P., Yao, W., Liu, W., Du, M., Guan, F., & Zang, X. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.09.008 · Cited by 73
“In prostate cancer, patients with strong intensity for B7x were at increased risk of clinical cancer recurrence and cancer-specific death [38].”
BackgroundSelf-citationZhou, B., Guangbo, Z., Ge, Y., Zhou, H., De-Sheng, L. V., & Zhang, X. (2014) · Journal of Surgical Research · doi:10.1016/j.jss.2014.01.014 · Cited by 72
Chen, L., Chen, J., Xu, B., Wang, Q., Zhou, W., Zhang, G., Sun, J., Shi, L., Pei, H., Wu, C., et al. (2015) · PubMed · Cited by 71
Metadata
- Authors
- Zang, X., Thompson, R. H., Al-Ahmadie, H. A., Serio, A. M., Reuter, V. E., Eastham, J. A., Scardino, P. T., Sharma, P., & Allison, J. P.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of Chicago Medical Center (US)
- Pathology, and
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Allison, James P.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2007-12-04
- Volume
- 104
- Issue
- 49
- Pages
- 19458-19463
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2148311
- OpenAlex
- W2164079212
- Cited by
- 401
- References
- 42
- Citations by year
- 2026: 20 · 2025: 15 · 2024: 20 · 2023: 23 · 2022: 27 · 2021: 28 · 2020: 22 · 2019: 19 · 2018: 21 · 2017: 26 · 2016: 31 · 2015: 15 · 2014: 22 · 2013: 25 · 2012: 27
- FWCI
- 11.81
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research Institute
- Prostate Cancer Foundation
- National Cancer Institute (T32CA082088)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- B7-H3, prostate cancer, B7/CD28 family, tumor immune evasion, tumor recurrence, cancer-specific mortality, lymph node metastasis, prognostic factors, immunotherapy targets, radical prostatectomy
- MeSH terms
- Humans, Immunohistochemistry, Male, Prognosis, Prostatic Neoplasms, Receptors, Immunologic, Antigens, CD, Survival Analysis, B7-1 Antigen, Disease Progression, B7 Antigens, V-Set Domain-Containing T-Cell Activation Inhibitor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.